SNMMI's communications staff is available to handle your inquiries, arrange interviews with experts, provide copies of research articles and more.
For assistance, please contact Rebecca Maxey, director of communications, at email@example.com or (703) 652-6772.
SNMMI is dedicated to being the premier source of information on nuclear medicine and molecular imaging. SNMMI's online newsroom provides reporters with the information needed to write articles and gain background information on the many topics related to molecular imaging and therapy and nuclear medicine.
SNMMI issues press releases on new research, society updates and industry news for members of the press. Check back frequently to see what's new with SNMMI.
View press releases on the latest research and news from SNMMI.
Nuclear and molecular imaging are vital elements of today's medical practice, adding an additional dimension to diagnosis that can change the way diseases are understood and treated. Nuclear medicine therapies treat specific diseases, such as lymphoma or thyroid cancer, by allowing a high dose of medicine to be delivered directly to a tumor or problem area. SNMMI's fact sheets explain how nuclear medicine and molecular imaging can help diagnose and/or treat a wide range of diseases.
SNMMI publishes two peer-reviewed medical journals—The Journal of Nuclear Medicine (JNM) and The Journal of Nuclear Medicine Technology (JNMT)—which feature the latest in molecular imaging research. JNM and JNMT are the most widely read peer-reviewed publications in molecular imaging, nuclear medicine and allied disciplines.
Every month, JNM brings readers around the globe clinical investigations, basic science reports, continuing education articles, book reviews, employment opportunities, and updates on rapidly changing issues in practice and research. JNM's Newsline offers in-depth reporting on news affecting every facet of the field—the latest scientific events, government decisions, industry developments, socio-economic trends, and a broad selection of reviews from the literature.
Published quarterly, JNMT focuses on technology, quality assurance, radiation safety, and the clinical applications of nuclear medicine. Each issue features continuing education articles written by leading educators in nuclear medicine technology as well as news and updates on practice, licensure, and credentialing for nuclear medicine technologists. Practitioners from across the imaging sciences turn to JNMT for peer-reviewed information related to daily clinical practice.
SNMMI can connect you with subject-matter experts on a variety of topics who are ready to respond to tight deadlines. Contact Rebecca Maxey, director of communications, at firstname.lastname@example.org or at (703) 652-6772, to set up an interview with SNMMI's leadership or with one of its many experts on oncology, brain disease, heart disease, radiopharmaceuticals, reimbursement and more.
Join SNMMI on our social media networks to stay updated on the latest from the society and the nuclear medicine and molecular imaging field.
SNMMI 2019 Annual Meeting
June 22-25, Anaheim, California
Stay tuned for more information.
A novel therapy using two targeted treatments for prostate cancer has been shown to maximize efficacy while reducing side effects.
Two research studies offer hope for effective treatment and prevention on acute kidney injury.
Research presented at the 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNM MI) shows preliminary evidence that tobacco smokers may have reduced neuroimmune function compared with nonsmokers.
Peptide receptor radionuclide therapy (PRRT) has been shown to be safe and effective for patients with grade 3 (G3) neuroendocrine neoplasms (NENs), according to research presented at SNMMI's 2019 Annual Meeting.
SNMMI monitors multiple federal legislative issues and provides resources including issue summaries, letters to Congress, and analysis. Most of this information is in the government relations news section of this web site.
Tools, supported by evidence, to harmonize the practice of nuclear medicine using a progressive and safe approach.